Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill for stomach paralysis shows promise in early trial

NCT ID NCT04026997

Terminated Symptom relief Sponsor: CinDome Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral drug called CIN-102 in 72 adults with gastroparesis (delayed stomach emptying) caused by diabetes or unknown reasons. Participants received one of three doses of CIN-102 or a placebo to see if it improved stomach emptying and reduced nausea. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CIN-102 (oral drug)
What this could lead to
If successful, CIN-102 could offer a new treatment option to improve stomach emptying and reduce nausea in people with gastroparesis.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. It is unclear if CIN-102 is effective or safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROPARESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis idiopathic gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROPARESIS

Contacts and locations

Locations

  • Research Site 101

    Chula Vista, California, 91910, United States

  • Research Site 102

    Boston, Massachusetts, 02215, United States

  • Research Site 103

    Louisville, Kentucky, 40202, United States

  • Research Site 104

    Monroe, Louisiana, 71201, United States

  • Research Site 105

    Tulsa, Oklahoma, 74104, United States

  • Research Site 106

    Philadelphia, Pennsylvania, 19140, United States

  • Research Site 107

    Jackson, Tennessee, 38305, United States

  • Research Site 109

    Great Neck, New York, 11023, United States

  • Research Site 110

    Kansas City, Kansas, 66045, United States

  • Research Site 111

    Atlanta, Georgia, 30322, United States

  • Research Site 112

    Marrero, Louisiana, 70072, United States

  • Research Site 113

    Las Vegas, Nevada, 89123, United States

  • Research Site 114

    Jacksonville, Florida, 32224, United States

  • Research Site 115

    Rapid City, South Dakota, 57702, United States

  • Research Site 117

    Miami, Florida, 33134, United States

  • Research Site 118

    Miami, Florida, 33183, United States

  • Research Site 119

    Summerville, South Carolina, 29485, United States

  • Research Site 120

    Winston-Salem, North Carolina, 27103, United States

  • Research Site 121

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.